Gain-of-function mutations in NLRP3 cause hereditary periodic fever syndromes that are collectively referred to as CAPS, and these patients are currently treated with biologics that target secreted IL-1 [12]. Here, NLRP3 is linked to cryopyrin-associated periodic syndrome.